Loading
Every dated change on the records linked to Hodgkin lymphoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Untreated advanced classical Hodgkin lymphoma with AVD, age ≥12
Nivolumab-AVD × 6 (S1826; approved March 2026, no routine radiotherapy) or BV-AVD × 6 with G-CSF (ECHELON-1); in Europe PET-guided BrECADD × 4-6 (HD21) or eBEACOPP; PET-adapted ABVD/AVD (RATHL) where novel agents unavailable. (NCCN Category 1 (nivolumab-AVD preferred; BV-AVD), ESMO-MCBS A (ECHELON-1))
ABVD × 4 + ISRT 30 Gy, or escalated BEACOPP × 2 + ABVD × 2 + RT (HD14/HD17 PET-guided); nivolumab- or BV-containing regimens in trials. (NCCN Category 2A)
Salvage (ICE, DHAP, GVD, BV-nivolumab or pembrolizumab-GVD) → PET-negative → high-dose therapy and autologous transplant; brentuximab consolidation for high-risk (AETHERA); PD-1 maintenance in trials. (NCCN Category 1 (ASCT after chemosensitive salvage; BV consolidation for high risk))
Pembrolizumab (KEYNOTE-204) or nivolumab; brentuximab vedotin if not yet given; BV + nivolumab; allogeneic transplant for fit patients after response; CD30 CAR-T in trials; palliative radiotherapy or bendamustine. (NCCN Category 1 (pembrolizumab, nivolumab, brentuximab))
ABVD × 2 + involved-site radiotherapy 20 Gy (HD10), or PET-adapted omission of radiotherapy after 3 cycles if PET-negative (RAPID, HD16) accepting ~5% lower PFS; AHOD2131 tests BV-nivo. (NCCN Category 1 (ABVD × 2 + ISRT 20 Gy or PET-adapted chemotherapy alone))
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
In the follicular lymphoma cohort, objective response 80.
4-year PFS 94.
A milestone in how this cancer is treated.
Five-year progression-free survival 85.
Omitting radiotherapy after a negative interim scan cost 7.
HD16: five-year progression-free survival 86.1 per cent without radiotherapy against 93.4 per cent with it after a negative scan. AHL2011: switching scan-negative patients from escalated BEACOPP to ABVD gave 85.7 against 86.2 per cent with grade 3 to 4 anaemia falling from 69 to 28 per cent.
First-line stage III/IV Hodgkin lymphoma with AVD
Relapsed or refractory classical Hodgkin lymphoma after two or more lines
A milestone in how this cancer is treated.
6-year OS 93.
Switching a positive interim scan to escalated BEACOPP raised five-year progression-free survival from 77.
Four cycles of escalated BEACOPP non-inferior to six or eight after a negative scan (five-year progression-free survival 92.
EORTC H10 raised five-year progression-free survival in scan-positive early-stage patients from 77.4 to 90.6 per cent by switching to escalated BEACOPP, but could not demonstrate non-inferiority of dropping radiotherapy after a negative scan in either risk group. HD18 shortened escalated BEACOPP to four cycles after a negative scan with five-year progression-free survival of 92.2 against 90.8 per cent and half the severe infections.
One-year overall survival 87.
ORR 69%.
15-year all-cause mortality among five-year survivors fell from 12.
3-year PFS 85.
A milestone in how this cancer is treated.
PFS HR 0.
A milestone in how this cancer is treated.
Schaapveld: 48.5 per cent of 3,905 survivors developed a second cancer within 40 years, with risk still 3.9 times the population rate after 35 years and no fall between the 1965 to 1976 and 1989 to 2000 treatment periods. Van Nimwegen: 50 per cent developed cardiovascular disease within 40 years.
Relapsed Hodgkin lymphoma and systemic ALCL
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Two cycles of ABVD with 20 Gy as effective as four cycles with 30 Gy (five-year freedom from treatment failure 91.
HD10 randomised 1,370 patients in a two by two design: five-year freedom from treatment failure 93.0 against 91.1 per cent for four against two cycles of ABVD (p = 0.39) and no difference between 30 Gy and 20 Gy (p = 1.00).